Lincoln National Corp’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,417
| Closed | -$618K | – | 473 |
|
|
2024
Q1 | $618K | Sell |
14,417
-478
| -3% | -$19.7K | 0.01% | 675 |
|
|
2023
Q4 | $552K | Buy |
14,895
+1,560
| +12% | +$56K | 0.01% | 639 |
|
|
2023
Q3 | $483K | Buy |
13,335
+171
| +1% | +$6.07K | 0.01% | 615 |
|
|
2023
Q2 | $469K | Buy |
13,164
+3,136
| +31% | +$112K | 0.01% | 632 |
|
|
2023
Q1 | $357K | Buy |
10,028
+1,564
| +18% | +$54.7K | 0.01% | 709 |
|
|
2022
Q4 | $297K | Sell |
8,464
-1,538
| -15% | -$51.2K | 0.01% | 717 |
|
|
2022
Q3 | $294K | Buy |
10,002
+861
| +9% | +$32.6K | 0.01% | 668 |
|
|
2022
Q2 | $497K | Buy |
9,141
+1,087
| +13% | +$60K | 0.01% | 483 |
|
|
2022
Q1 | $438K | Buy |
8,054
+1,107
| +16% | +$60.1K | 0.01% | 581 |
|
|
2021
Q4 | $383K | Buy |
6,947
+747
| +12% | +$38.9K | 0.01% | 626 |
|
|
2021
Q3 | $296K | Sell |
6,200
-529
| -8% | -$26.6K | 0.01% | 687 |
|
|
2021
Q2 | $335K | Buy |
6,729
+354
| +6% | +$17K | 0.01% | 624 |
|
|
2021
Q1 | $284K | Sell |
6,375
-807
| -11% | -$36.6K | 0.01% | 633 |
|
|
2020
Q4 | $330K | Sell |
7,182
-2,875
| -29% | -$132K | 0.01% | 543 |
|
|
2020
Q3 | $473K | Sell |
10,057
-89
| -0.9% | -$4.46K | 0.01% | 392 |
|
|
2020
Q2 | $517K | Buy |
10,146
+2,420
| +31% | +$124K | 0.02% | 369 |
|
|
2020
Q1 | $366K | Buy |
7,726
+84
| +1% | +$4.48K | 0.01% | 396 |
|
|
2019
Q4 | $449K | Buy |
7,642
+1,568
| +26% | +$87.2K | 0.01% | 416 |
|
|
2019
Q3 | $324K | Sell |
6,074
-51
| -0.8% | -$2.62K | 0.01% | 437 |
|
|
2019
Q2 | $306K | Buy |
6,125
+231
| +4% | +$11.6K | 0.01% | 416 |
|
|
2019
Q1 | $308K | Sell |
5,894
-259
| -4% | -$12.9K | 0.01% | 383 |
|
|
2018
Q4 | $294K | Sell |
6,153
-382
| -6% | -$18.8K | 0.01% | 355 |
|
|
2018
Q3 | $328K | Sell |
6,535
-108
| -2% | -$5.49K | 0.01% | 343 |
|
|
2018
Q2 | $334K | Sell |
6,643
-423
| -6% | -$21.3K | 0.01% | 344 |
|
|
2018
Q1 | $345K | Sell |
7,066
-3,260
| -32% | -$152K | 0.01% | 338 |
|
|
2017
Q4 | $457K | Buy |
10,326
+5,786
| +127% | +$267K | 0.01% | 389 |
|
|
2017
Q3 | $231K | Buy |
4,540
+41
| +0.9% | +$2.08K | 0.01% | 365 |
|
|
2017
Q2 | $242K | Buy |
+4,499
| New | +$240K | 0.01% | 303 |
|
|
2016
Q4 | – | Sell |
-4,734
| Closed | -$255K | – | 312 |
|
|
2016
Q3 | $255K | Buy |
4,734
+888
| +23% | +$48.7K | 0.01% | 240 |
|
|
2016
Q2 | $208K | Buy |
+3,846
| New | +$203K | 0.01% | 253 |
|
Other funds holding GSK
JEST
Lincoln National Corp's GSK Position: Q2 2024 in Review
Lincoln National Corp sold out of GSK (GSK) in Q2 2024, closing a stake of 14,417 shares — an estimated $618K sold.
Lincoln National Corp first reported a position in GSK in Q2 2016 and held it in 30 quarters. The position peaked at $618K in Q1 2024. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.
- Lincoln National Corp reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
- Lincoln National Corp sold 14,417 GSK shares in Q2 2024, an estimated $618K.
- Lincoln National Corp first reported a position in GSK in Q2 2016 and held it in 30 quarters.
- Lincoln National Corp's GSK position peaked at $618K in Q1 2024.
- 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.
Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.